Histogenics Corporation (NASDAQ:HSGX) Releases Earnings Results, Beats Expectations By $0.06 EPS
Histogenics Corporation (NASDAQ:HSGX) announced its earnings results on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06, Bloomberg Earnings reports. During the same period last year, the business earned ($0.61) EPS.
Shares of Histogenics Corporation (NASDAQ:HSGX) traded down 0.4000% during midday trading on Thursday, hitting $1.7928. The stock had a trading volume of 69,432 shares. The stock has a 50 day moving average price of $1.83 and a 200-day moving average price of $1.73. Histogenics Corporation has a 52 week low of $1.45 and a 52 week high of $4.47. The stock’s market capitalization is $39.74 million.
ILLEGAL ACTIVITY WARNING: “Histogenics Corporation (NASDAQ:HSGX) Releases Earnings Results, Beats Expectations By $0.06 EPS” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/histogenics-corporation-nasdaqhsgx-releases-earnings-results-beats-expectations-by-0-06-eps/1469791.html.
A number of equities research analysts have recently issued reports on HSGX shares. Zacks Investment Research raised Histogenics Corporation from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Tuesday, May 16th. HC Wainwright set a $4.00 target price on Histogenics Corporation and gave the stock a “buy” rating in a research report on Saturday, May 13th. Canaccord Genuity reaffirmed a “buy” rating on shares of Histogenics Corporation in a research report on Thursday, May 11th. Finally, ValuEngine raised Histogenics Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Histogenics Corporation presently has a consensus rating of “Hold” and an average target price of $5.10.
A number of hedge funds have recently modified their holdings of the company. Sabby Management LLC increased its stake in shares of Histogenics Corporation by 15.9% in the first quarter. Sabby Management LLC now owns 1,095,422 shares of the biotechnology company’s stock valued at $1,895,000 after buying an additional 150,531 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Histogenics Corporation by 51.1% in the fourth quarter. Renaissance Technologies LLC now owns 99,000 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 33,500 shares during the last quarter. Finally, Carl Domino Inc increased its stake in shares of Histogenics Corporation by 2.8% in the first quarter. Carl Domino Inc now owns 89,400 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,400 shares during the last quarter. 50.09% of the stock is currently owned by institutional investors and hedge funds.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.